Tirzepatide 20 mg (GLP1+GIP)

Tirzepatide 20mg - molecular characterization

Thirzepatide 20mg is a synthetic peptide with a molecular weight of approximately 4813 Da, designed as a dual agonist for GIPR and GLP-1R receptors. The molecule contains a modified amino acid sequence and a lipid chain that allows reversible binding to albumin, which prolongs the half-life and increases stability in the biological environment.

According to pharmacological analyses described in a review by Min et al. (2023), tirzepatide shows the ability to activate incretin receptors through a Gs protein-dependent mechanism, leading to an increase in cAMP levels and activation of downstream signaling cascades.

Thiothrombate 20mg receptor mechanism - data from preclinical and clinical studies

Dual activation of GIPR and GLP-1R leads to:

• An increase in glucose-dependent insulin secretion,

• Inhibition of glucagon secretion under hyperglycemic conditions,

• Slowing gastric emptying,

• Effects on central mechanisms regulating appetite.

In vitro studies have shown that activation of these receptors increases cAMP levels and modulates the expression of genes related to glucose and lipid metabolism.

A mechanistic review (Min T. et al., 2023) emphasizes that simultaneous activation of GIP and GLP-1 can lead to a synergistic effect beyond the sum of the effects of the individual agonists.

Source:
https://pmc.ncbi.nlm.nih.gov/articles/PMC10107501/

Results of clinical trials - analysis of highest exposure levels

In the SURMOUNT-1 study published in the New England Journal of Medicine (2022) evaluated the effect of tirzepatydu on body weight at 72-week follow-up.

For the highest dose analyzed in the study (15 mg), they reported:

• average weight reduction of 20.9%,

• ≥20% weight reduction in more than 50% participants,

• improving lipid parameters and lowering systolic blood pressure.

In SURPASS-2 (NEJM 2021), it was shown that tirzepatide led to greater reductions in HbA1c than Semaglutide And to a significant reduction in body weight.

Sources:
https://pubmed.ncbi.nlm.nih.gov/35658024/
https://pubmed.ncbi.nlm.nih.gov/34170647/

These data indicate a clear dose-dependent effect and intensity of receptor activation.

Research significance of the tirzepatid 20mg variant

Although registration studies have analyzed doses up to 15 mg, the 20 mg variant provides a model in the laboratory setting for evaluation:

• maximum activation of incretin receptors,

• dose-response relationships,

• GPCR signaling intensity,

• metabolic effects at higher receptor exposure.

In animal models, activation of the GIP/GLP-1 axis led to changes in the expression of genes related to lipid metabolism and regulation of carbohydrate metabolism.

The nature and quality of the material

Tirzepatide 20 mg offered as test material is a reference substance for biochemical and pharmacological analyses.

Product quality should be confirmed by analytical documentation (e.g., HPLC profile, certificate of analysis - CoA), ensuring reproducibility of experimental results.

The product is intended for research and analytical use only (Research Use Only).

Thirzepatide vs Semaglutide vs Retatrutide - receptor mechanism

Semaglutide, Tirzepatide and Retatrutide belong to a group of advanced incretin agonists that differ in the extent of receptor activation and pharmacodynamic profile.

Semaglutide acts selectively on the GLP-1R receptor. Activation of this receptor leads to an increase in cAMP levels, modulation of the insulinotropic response and effects on central mechanisms regulating appetite.

Tirzepatide, including a variant referred to as tirzepatid 20mg, exhibits a dual mechanism of action through simultaneous activation of GLP-1R and GIPR receptors. Integration of these two incretin axes leads to the enhanced cAMP-dependent response and pronounced dose-dependent effect observed in clinical trials. The literature indicates that dual GIP + GLP-1 agonism can generate a synergistic effect beyond that of a selective GLP-1 agonist.

Retatrutide represents a more complex model - it activates GLP-1R, GIPR and glucagon receptor (GCGR). Such triagonism expands the metabolic response to include additional mechanisms related to the regulation of lipid and energy substrate metabolism.

To summarize mechanistically:

• semaglutide - a selective GLP-1R agonist,

• tirzepatide / tirzepatid 20mg - dual agonist of GLP-1R and GIPR,

• retatrutide - a triagonist of GLP-1R, GIPR and GCGR.

The range of activated receptors is a key element in differentiating these molecules in pharmacological studies.

Thirzepatide 20mg - availability and where to buy (research nature)

In a laboratory context tirzepatid 20mg functions as a reference material for research use only (Research Use Only).

Substances of this type are offered by specialized suppliers of reagents and analytical materials that provide:

• Quality documentation (Certificate of Analysis - CoA),

• A confirmed purity profile (e.g., HPLC),

• Batch identification and storage conditions.

In research marketing, it is important to confirm the analytical quality and compatibility with the experimental purpose.

The product is not intended for stand-alone therapeutic use or for use outside controlled trials.

See also Tirzepatide 20 mg in device (Pen)

Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.